Correlation Engine 2.0
Clear Search sequence regions

  • apixaban (1)
  • dabigatran (1)
  • drug levels (1)
  • female (1)
  • humans (1)
  • patients (1)
  • rivaroxaban (1)
  • Sizes of these terms reflect their relevance to your search.

    New, target specific, oral anticoagulants have been shown to be safe and effective in prevention and treatment of thromboembolism without laboratory monitoring. However, clinical use of the drugs dabigatran, rivaroxaban, and apixaban requires laboratory measurement of their anticoagulant effect in specific clinical situations. This paper reviews the data available on use of screening and specialized testing to measure the anticoagulant effect and drug levels in patients prescribed these medications. Their effect on other coagulation assays is also reviewed.


    Barbara A Konkle. Monitoring target specific anticoagulants. Journal of thrombosis and thrombolysis. 2013 Apr;35(3):387-90

    Expand section icon Mesh Tags

    Expand section icon Substances

    PMID: 23381464

    View Full Text